The estimated Net Worth of John Kenneth Jenkins is at least $273 Tysiąc dollars as of 15 March 2019. Mr. Jenkins owns over 1,000 units of Corbus Pharmaceuticals Inc stock worth over $52,710 and over the last 6 years he sold CRBP stock worth over $0. In addition, he makes $220,622 as Independent Director at Corbus Pharmaceuticals Inc.
John has made over 1 trades of the Corbus Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of CRBP stock worth $6,980 on 15 March 2019.
The largest trade he's ever made was buying 1,000 units of Corbus Pharmaceuticals Inc stock on 15 March 2019 worth over $6,980. On average, John trades about 77 units every 0 days since 2018. As of 15 March 2019 he still owns at least 1,000 units of Corbus Pharmaceuticals Inc stock.
You can see the complete history of Mr. Jenkins stock trades at the bottom of the page.
John Kenneth Jenkins M.D. serves as Independent Director of the Company. Dr. Jenkins has served as a director since June 2018. Dr. Jenkins has served as Principal, Drug and Biological Products at Greenleaf Health, a strategic, U.S. Food and Drug Administration (“FDA”)-focused regulatory consulting firm helping companies developing new drugs and seeking FDA approval, since February 2017. Previously, Dr. Jenkins worked in various positions of increasing responsibility at FDA from May 1992 until his retirement in January 2017. Dr. Jenkins began his FDA career in 1992, where he was a medical officer in the Division of Oncology and Pulmonary Drug Products. He subsequently served as Pulmonary Medical Group Leader and Acting Division Director before being appointed as Director of the Division of Pulmonary Drug Products in 1995. He became the Director of the Office of Drug Evaluation II in 1999 and remained in that position until he was appointed Director of the Office of New Drugs in 2002. Prior to joining the FDA, Dr. Jenkins served as an Assistant Professor of Pulmonary and Critical Care Medicine at VCU/MCV, and as a Staff Physician at the Hunter Holmes McGuire VA Medical Center in Richmond, Virginia. Dr. Jenkins is board certified in internal medicine and pulmonary diseases by the American Board of Internal Medicine. He received his medical degree from the University of Tennessee, Memphis and completed his post-graduate medical training in internal medicine, pulmonary diseases, and critical care medicine at Virginia Commonwealth University/Medical College of Virginia in Richmond. Dr. Jenkins was selected as a director due to his medical knowledge and strategic regulatory expertise.
As the Independent Director of Corbus Pharmaceuticals Inc, the total compensation of John Jenkins at Corbus Pharmaceuticals Inc is $220,622. There are 8 executives at Corbus Pharmaceuticals Inc getting paid more, with Yuval Cohen having the highest compensation of $4,001,510.
John Jenkins is 62, he's been the Independent Director of Corbus Pharmaceuticals Inc since 2018. There are 4 older and 6 younger executives at Corbus Pharmaceuticals Inc. The oldest executive at Corbus Pharmaceuticals Holdings Inc is Avery Catlin, 72, who is the Independent Director.
John's mailing address filed with the SEC is 500 River Ridge Dr, Norwood, MA 02062, USA.
Over the last 10 years, insiders at Corbus Pharmaceuticals Inc have traded over $3,643,182 worth of Corbus Pharmaceuticals Inc stock and bought 2,676,074 units worth $50,292,165 . The most active insiders traders include Asset Management, Lp Chen B..., Asset Management, Lp Cormor... oraz Sean F. Moran. On average, Corbus Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $1,059,576. The most recent stock trade was executed by Sean F. Moran on 14 June 2024, trading 18,043 units of CRBP stock currently worth $233,837.
corbus pharmaceuticals holdings, inc. (nasdaq: crbp) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. the company's lead product candidate, resunab™, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. resunab is scheduled to commence three phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. resunab also has the potential to treat additional rare, inflammatory diseases.
Corbus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: